Chronic myelomonocytic leukemia (CMML) is described as an aggressive hematologic malignancy characterized by excessive inflammatory signaling and clonal myeloproliferation. The role of neutrophils, and specifically neutrophil-mediated inflammation, in CMML has been incompletely defined. In this reported study, primary neutrophils (polymorphonuclear cells, PMNs) isolated from CMML patients exhibited an aberrant increase in baseline formation of neutrophil extracellular traps (NETs) relative to what would be expected in non-malignant contexts. The authors frame increased NET formation as a potentially important contributor to the inflammatory microenvironment in CMML.
Alongside elevated baseline NET formation, the study notes that CMML PMNs are transcriptionally primed for NETosis. This finding indicates that neutrophils from CMML patients harbor gene-expression changes that favor NET formation, rather than NETosis being solely a secondary response to external stimuli. The source abstract does not provide detailed transcriptomic results, gene lists, or pathway analyses; those experimental specifics were not reported in the abstract and would need to be consulted in the full manuscript.
A central observation reported is that soluble factors produced during NET formation by CMML neutrophils promote clonogenicity of patient-matched CMML CD34+ hematopoietic cells. In other words, products released during NETosis appear to enhance the colony-forming capacity of malignant progenitor cells from the same patients. This establishes a mechanistic link between neutrophil-driven inflammation and expansion of the malignant hematopoietic clone in CMML. The abstract does not enumerate the specific soluble mediators responsible, nor the experimental conditions, colony assays, or quantitative effect sizes; those details were not reported in the abstract and should be reviewed in the full preprint for experimental design and validation.
The authors evaluated NET inhibition using a novel peptide called neonatal NET-inhibitory factor (nNIF). According to the abstract, nNIF effectively inhibits NETosis in the CMML neutrophil system. In addition, clinical agents under investigation for CMML treatment also reduced NET formation in the assays reported. These results support the concept that NET-targeting strategies—whether via peptide inhibitors like nNIF or repurposed/experimental clinical agents—can suppress NETosis in CMML-derived neutrophils. The abstract does not list the investigational agents tested, nor does it provide dose–response data or comparative potency; those experimental particulars were not described in the abstract.
Based on the observations summarized above, the authors propose that dysregulated NET formation constitutes a previously unrecognized driver of CMML clonogenicity and represents a therapeutic vulnerability. The suppression of NETosis by nNIF and by investigational CMML agents suggests that NET inhibition could be a rational adjunct or therapeutic avenue for a disease with limited current treatment options. The authors recommend further study of NET inhibitory agents in CMML, presumably including detailed preclinical validation and eventual clinical translation. Specific recommendations for clinical development, patient selection, biomarkers of NET activity, or combination strategies were not provided in the abstract and would require consultation of the full manuscript.
This report is a preprint posted to bioRxiv and has not been peer reviewed; conclusions should therefore be interpreted as preliminary. A competing interest is disclosed: one author (A.B.P.) receives research funding from Genentech–Roche and Novartis. Funding sources listed include grants and support from the National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Heart, Lung, and Blood Institute Division of Intramural Research. The abstract and article metadata confirm these declarations.
Notes on limitations and missing details
The source for this rewrite was the preprint abstract and article metadata; the abstract reports the principal findings but omits many experimental specifics. Quantitative results, cohort sizes, detailed methods (for NET assays, transcriptomics, colony-forming assays), identities of the soluble mediators, and the names/doses of investigational clinical agents that inhibited NETosis were not reported in the abstract. Those items are necessary to assess effect magnitude, reproducibility, and clinical translatability and should be reviewed in the full preprint or subsequent peer-reviewed publication.
Concluding summary
In summary, the preprint identifies aberrant neutrophil extracellular trap formation and transcriptional priming for NETosis in CMML neutrophils, links NET-derived soluble factors to increased clonogenicity of patient-matched CD34+ cells, and demonstrates NET suppression by the peptide nNIF and by clinical agents under investigation for CMML. The authors propose NETosis as a novel mechanistic driver and therapeutic vulnerability in CMML and call for further study of NET inhibitory approaches. Given the preprint status, further peer-reviewed validation is needed.